- Ampio Pharmaceuticals (AMPE) soars 34% premarket after saying the endogenous immunomodulatory molecule Ampion met its primary endpoint in a study evaluating the treatment's ability to reduce pain in patients with osteoarthritis of the knee.
- Orthopedic surgeon Dr. Brian McGrath, the study's principal investigator, calls the results "fantastic" and notes that it "may soon be possible to offer OAK patients an effective [injectable] therapy." (PR)
Ampion effective in study, Ampio shares soar
Aug 14 2013, 08:54 ET